Elasmogen is led by industry professionals with broad experience that covers both big Pharma and early-stage biotech. The team has a demonstrated track-record of delivering biologic drugs to the clinic and of securing company exits via trade-sale and IPO.
Mr Jones brings 25 years of success leading new medical products from concept through to market adoption in VC and Fortune 500 companies. Currently Chairman of Mologic, and NED for Deltex Medical, MediSieve and Health Enterprise East, Mr Jones is a US national who came to the UK in 2008 to become CEO of GlySure. He has raised over $40 M in funding from Venture, Corporate and Angel investors. At GlySure he led the development and CE approval of the world’s first continuous intravascular glucose sensor. From 2005-2008 he was CEO of Tensys Medical developing and commercialising the first continuous NIBP monitor resulting in the sale of the company in 2008. In his current role Mr Jones provides both strategic direction and hands-on support for critical areas including: market assessment, commercialisation, partnerships and IP strategy. Mr Jones is a graduate of Yale University with a B.S. in Molecular Biophysics and Biochemistry.
Dr Caroline Barelle
With postgraduate qualifications in both business and science, Caroline has a strong commercial, bio-partnering and biologics drug discovery/development background. For over 4 years she has successfully led teams at Wyeth Inc and subsequently Pfizer Inc in Global Bio-therapeutic Technologies progressing early platform technologies to late stage clinical development. Prior to this she was Alliance and Programs Manager at Haptogen Ltd and a key part of the acquisition team that successfully exited the business to Wyeth Inc.
She has been awarded a prestigious Royal Society of Edinburgh commercialisation Fellowship and is a doctoral graduate from the University of Aberdeen in Biochemistry.
Professor Andy Porter FRSB, FRSE
Chief Technical Officer
Andy is currently Professor of Medical Biotechnology, University of Aberdeen, Scotland and Director of the Scottish Biologics Facility. He was founder and CSO of the University spin-out Haptogen Ltd. until it was acquired, in October 2007, by Wyeth Inc. In 2005 he was made the Ernst and Young Plc, UK Science and Technology Entrepreneur of the Year. In 2006 he became a Fellow of the Royal Society of Edinburgh and a Fellow of the Royal Society of Biology in 2012. Andy has been on the Board of the biologics company NovaBiotics Ltd since 2009. NovaBiotics currently has two products in Ph 2 clinical trials, a global licensing deal with Taro Inc and a City funding round by Woodford Investment Management. Andy is a graduate of St Andrew’s University.